Publication Date:
2015-08-05
Description:
Article Despite normalization of the CA125 serum biomarker at the completion of carboplatin therapy the vast majority of patients with high grade serous ovarian cancers relapse. Here, Janzen et al ., identify a sub-population of tumor cells that are CA125 negative, cancer initiating and platinum resistant but readily eliminated with the addition of apoptosis enhancing drugs to carboplatin. Nature Communications doi: 10.1038/ncomms8956 Authors: D. M. Janzen, E. Tiourin, J. A. Salehi, D. Y. Paik, J. Lu, M. Pellegrini, S. Memarzadeh
Electronic ISSN:
2041-1723
Topics:
Biology
,
Chemistry and Pharmacology
,
Natural Sciences in General
,
Physics
Permalink